Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00507702 · ClinicalTrials.gov registry record
Identification of Key Blood Molecular Markers for Immunotherapy
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 191
- Enrollment target
NCT00507702: Clinical Trial study, sponsored by Stanford University.
NCT00507702 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 191 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00507702 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 191 participants
- Enrollment target
Study Summary
To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.
Interventions
- PROCEDURE phlebotomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2006-07-06 |
| Est. Completion | 2015-02-25 |
Why NCT00507702 stopped before completion
NCT00507702 is an observational study that tracks outcomes without assigning an intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which phlebotomy is the first listed.
NCT00507702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00507702 about?
NCT00507702 is a clinical study titled "Identification of Key Blood Molecular Markers for Immunotherapy". To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.
What is the current status of trial NCT00507702?
This trial is currently terminated. The enrollment target is 191 participants. The study started on 2006-07-06. Estimated completion is 2015-02-25.
What interventions are being tested in trial NCT00507702?
The interventions under investigation include: phlebotomy (PROCEDURE).
Who is sponsoring clinical trial NCT00507702?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI